The Grunenthal Group

What The Grunenthal Group does

Grünenthal Group is a privately-owned, science-based pharmaceutical company headquartered in Aachen, Germany, founded in 1946 and operating globally with approximately 4,300 employees across 28 country affiliates. The company is exclusively focused on pain management and related diseases, applying expertise in neurobiology, neuronal hyper- and hypoexcitability, sensory biology, neuronal health, and neuroinflammation to address acute and chronic pain conditions. Products are made available to patients in approximately 100 countries through direct affiliates and licensing partnerships. Leadership is led by CEO Gabriel Baertschi, with CFO Fabian Raschke, CCO Jan Adams, and CSO Uli Brödl on the executive team.

The company's commercial portfolio combines acquired established brands and proprietary pipeline assets. Core marketed products include Movantik® (naloxegol) for opioid-induced constipation—acquired in 2024 via the approximately $250 million all-stock acquisition of Valinor Pharma and generating over $200 million in US sales in 2023—Qutenza® (capsaicin), a topical non-opioid patch for peripheral neuropathic pain, and Nebido® (testosterone undecanoate) for male hypogonadism. The R&D pipeline features a proprietary orally administered voltage-gated sodium channel (NaV) 1.8 inhibitor that entered Phase I clinical trials in February 2026 with results expected in H2 2026, targeting non-opioid pain therapy. Grünenthal also holds full ownership since March 2026 of the Grünenthal Meds portfolio — 12 established brands across 6 therapeutic areas in over 60 markets, previously a joint venture with Kyowa Kirin International.

Grünenthal operates a fully integrated pharmaceutical business model, generating revenue through direct sales of branded products via field salesforces to healthcare providers, hospitals, and pharmacies, supplemented by licensing and royalty agreements with regional partners (BCWorld Pharm in South Korea, Clinect in Australia, Apotex/Searchlight Pharma in Canada). The company pursues an explicit M&A-driven growth strategy targeting established brands that deliver rapid financial returns and synergies across manufacturing, logistics, and commercial operations. FY2024 revenue was approximately €1.8 billion. Distribution infrastructure includes manufacturing sites in Switzerland (Mitlödi), Italy (Origgio), and Chile (Santiago), with regional sales and marketing offices across Europe, Latin America, and the US (Morristown and Boston).

Name

The Grunenthal Group

Legal name

Grünenthal GmbH

Website

https://grunenthal.com

Company type

Private

Founded year

1946

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Grünenthal is a privately-owned, science-based pharmaceutical company headquartered in Aachen, Germany, focused exclusively on pain management and related diseases. It markets Movantik®, Qutenza®, and Nebido® across approximately 100 countries, with a €1.8 billion FY2024 revenue base and a proprietary NaV 1.8 inhibitor in Phase I clinical development.

Ownership category

akta.pro rank

Product category

Pain Management Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Pain management pharmaceuticals
• Non-opioid pain therapy
• Peripheral neuropathic pain
• Opioid-induced constipation treatment
• Established medicines portfolio

Headquarters

HQ city

Aachen

HQ country

Germany

HQ region

Europe

Offices20 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Grünenthal generates revenue primarily through the sale of proprietary and established pharmaceutical products across its portfolio of pain management and related disease treatments. The company operates a fully integrated model from R&D through commercialization.
2. Licensing and Royalty Revenue: Grünenthal licenses its products (Qutenza®, Nebido®) to regional partners in exchange for upfront payments, regulatory milestone payments, and margins or royalties on sales. Examples include BCWorld Pharm (South Korea), Clinect (Australia), and Apotex (Canada).

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Grünenthal is a science-based, fully integrated pharmaceutical company that develops, manufactures, and commercializes branded prescription medicines for pain management and related diseases, including Movantik® (naloxegol) for opioid-induced constipation, Qutenza® (capsaicin 8% patch) for peripheral neuropathic pain, and Nebido® (testosterone undecanoate) for male hypogonadism, while advancing a proprietary NaV 1.8 inhibitor pipeline for non-opioid pain therapy. The company grows through M&A of established brands and direct commercial sales via 28 country affiliates serving approximately 100 countries.

Product overview

Grünenthal is a science-based, privately-owned pharmaceutical company and global leader in pain management. The company operates as a fully integrated pharmaceutical organization offering established pain medications alongside an active R&D pipeline focused on non-opioid therapies. Key products include Movantik® (naloxegol) for opioid-induced constipation, Qutenza® for peripheral neuropathic pain, and Nebido® for testosterone replacement. Grünenthal acquired Valinor Pharma in 2024 for approximately $250 million, gaining global rights to Movantik®, and took full ownership of the Grünenthal Meds portfolio (12 established brands across 6 therapeutic areas) in 2026. The company's innovation pipeline includes a proprietary NaV 1.8 inhibitor currently in Phase I trials for non-opioid pain therapy and Tegacorat (GRM-01). Products are available in approximately 100 countries, with commercial operations spanning Europe, Latin America, and the United States through 28 country affiliates.

Differentiator

Problem solved

Functional benefit

Brands

• Grünenthal PRO: Full-service CMO service offering
• Grünenthal Health

Products and services

• Movantik® (naloxegol) Oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Generated over $200 million in US sales in 2023 and is sold to healthcare providers and pain specialists globally through Grünenthal's commercial affiliates.
• Qutenza® (capsaicin 8% topical patch) Topical non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Applied by healthcare professionals and pain specialists in clinical settings; licensed to regional distribution partners in select markets.
• Nebido® (testosterone undecanoate) Long-acting injectable testosterone replacement therapy for male hypogonadism. Out-licensed to regional partners in selected markets.
• Grünenthal Meds portfolio Portfolio of 12 established brands across six therapeutic areas available in over 60 markets, providing a diversified specialty pharma commercial platform.
• NaV 1.8 inhibitor (proprietary investigational program) Proprietary, orally administered, voltage-gated sodium channel (NaV) 1.8 inhibitor being developed as a non-opioid therapy option across a range of acute and chronic pain conditions. Currently in Phase I clinical development.
• Tegacorat (GRM-01) Pipeline asset referenced in the Tegacorat digital library section of Grünenthal's science website, associated with the company's research in pain-adjacent indications and Duchenne muscular dystrophy.

Quantifiable outcome

• Movantik® generated over $200 million in US sales in 2023 following Valinor Pharma's commercial innovations.
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered regional and core.

• BCWorld PharmregionalChannel Partner/ Reseller/ Distributor · 5 March 2026Grünenthal and BCWorld Pharm entered into an agreement granting BCWP exclusive rights to market Qutenza® in South Korea. Grünenthal will receive payments upon regulatory approval and sales, with BCWP responsible for obtaining marketing authorization and distribution.
• Kyowa Kirin InternationalcoreStrategic or Co-development Partner · 2 March 2026Grünenthal acquired Kyowa Kirin International's 49% stake in the 'Grünenthal Meds' joint venture, taking full ownership of the portfolio and operations. The joint venture was established in 2023 and comprised a portfolio of 12 established brands across six therapeutic areas and over 60 markets. Integration was expected to be completed by June 2026.
• Clinect Pty LtdregionalChannel Partner/ Reseller/ Distributor · 24 February 2026Grünenthal granted Clinect exclusive Australian rights to Qutenza®, a topical non-systemic, non-opioid patch for peripheral neuropathic pain. Clinect handles marketing authorization and distribution in Australia, a major Asia-Pacific market. This aligns with Grünenthal's strategy to expand Qutenza®'s global footprint.
• Apotex Inc. / Searchlight PharmaregionalChannel Partner/ Reseller/ Distributor · 5 February 2026Grünenthal and Apotex entered into a licensing agreement granting Apotex exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable testosterone replacement therapy for male hypogonadism. Apotex's branded division Searchlight Pharma will pursue regulatory approval and market and distribute the product in Canada. Grünenthal receives upfront payment, regulatory milestone payments, and a margin on sales.
• Apotex Inc. / Searchlight PharmaregionalChannel Partner/ Reseller/ Distributor · 24 February 2025Grünenthal granted Apotex exclusive Canadian rights to Qutenza®, a topical non-systemic, non-opioid pain patch for neuropathic pain management. Apotex's specialty division Searchlight Pharma will pursue regulatory approval and market the product in Canada, with Grünenthal receiving upfront, regulatory milestone, and royalty payments.
• Valinor Pharma (Acquisition)coreStrategic or Co-development Partner · 22 July 2024Grünenthal acquired US-based Valinor Pharma in an all-stock deal valued at approximately $250 million, gaining global ownership of Movantik® (naloxegol) for opioid-induced constipation. Valinor had improved Movantik's commercial platform, leading to 150% revenue increase in Q1 2024 and record EBITDA. The deal enhances Grünenthal's presence in the US pain management market.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vertex Pharmaceuticals: Vertex's Journavx (suzetrigine) is a recently approved non-opioid pain therapy, making Vertex the most direct competitor in novel pain mechanisms. Both companies target the same unmet need for non-opioid analgesics with proprietary R&D pipelines.
• Collegium Pharmaceutical: US specialty pharma focused on pain management with established branded products (Xtampza, Nucynta). Comparable mid-sized pain-focused commercial model targeting similar prescriber base of pain specialists.
• Purdue Pharma: Private pain-focused pharmaceutical company with similar legacy in pain therapeutics and pivot toward non-opioid approaches. Directly comparable in therapeutic focus, though currently operating under Chapter 11 restructuring.
• Endo International: Specialty pharma with pain management franchise including products for neuropathic and chronic pain. Operates a similar branded-pain model targeting prescribers in the same therapeutic area.

Emerging players

• Cara Therapeutics: Clinical-stage biopharma developing novel pain and pruritus therapeutics, including Korsuva (difelikefalin). Comparable in therapeutic focus on pain-adjacent indications with a smaller, more pipeline-driven profile.
• Scilex Holding: Specialty pharma focused on non-opioid pain management with ZTlido (lidocaine patch) and Sprix/ELYXYB. Smaller and earlier-stage than Grünenthal but directly comparable in non-opioid pain commercial model.
• Jazz Pharmaceuticals: Specialty pharma with growing neuroscience and pain presence including Xywav for narcolepsy and emerging pain assets. Mid-cap peer with comparable focus on CNS/pain-adjacent therapeutics.

Broad incumbents

• Teva Pharmaceutical Industries: Global generic and specialty pharma with a meaningful pain franchise (including Ajovy for migraine). Overlaps in pain therapeutics but operates across far broader therapeutic areas.
• Pfizer: One of the largest global pharma companies with established pain and neuroscience franchises. Competes broadly in the same therapeutic categories but at much greater scale and across all major indications.
• Eli Lilly: Major pharma with significant pain and migraine portfolio (Emgality, Reyvow) and active neuroscience pipeline. Larger incumbent operating across multiple therapeutic areas including pain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCyLvh5Nldpbsojxa8URjqVg
• Facebookfacebook.com/Caring-for-Change-1975323459367353
• LinkedInlinkedin.com/company/gruenenthal
• Instagraminstagram.com/grunenthal
• Xx.com/grunenthalgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries12 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Grunenthal Group